Clinical trials: Airway Inflammation
Airway Inflammation, Asthma
An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients
This is a randomised, active-comparator, open-label, parallel-group, multicentre phase IV exploratory study to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA…
- Trial name
- NCT03924635
- Testing
- SYMBICORT and salbutamol
- Where
- 6 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma, Airway Inflammation
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation…
- Trial name
- NCT00635882
- Testing
- mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, mometasone furoate/formoterol 400/10 mcg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Chronic Obstructive Pulmonary Disease (COPD)
Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease
Objective: To characterize FeNO levels that may be indicative of eosinophilic airway inflammation in patients with chronic obstructive airways disease Number of participants: Approximately 200 subjects will be enrolled Reference…
- Trial name
- NCT01634620
- Testing
- NIOX MINO® Instrument (09-1100)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Aerocrine AB
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma.
- Trial name
- EXPEDITION (NCT02573233)
- Testing
- Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 42 people
- Sponsor
- Sanofi
COPD
A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
This was a 2 Part study. Part 1 was a safety and tolerability study in GOLD I-III COPD patients. Part 2 was an efficacy study in GOLD I-III COPD patients.
- Trial name
- NCT01972776
- Testing
- QBM076
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Asthma, Bronchial Diseases
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive
- Trial name
- CASCADE (NCT03688074)
- Testing
- Tezepelumab
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
- Trial name
- AERIFY-3 (NCT05326412)
- Testing
- Itepekimab SAR440340
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Asthma
Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Controlled on Inhaled…
- Trial name
- MESOS (NCT02449473)
- Testing
- Tralokinumab
- Where
- 15 sites in Canada, Denmark and 1 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Asthma
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
This is an exploratory study with the following primary objectives: 1) to establish that PET/CT of the lung can reliably distinguish healthy, non-asthmatic participants from participants with severe asthma and an eosinophilic…
- Trial name
- DEAR (NCT02937168)
- Testing
- Reslizumab, Fludeoxyglucose F 18 (FDG)
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Nasal Congestion and Inflammations
Sonu Nasal Congestion Relief Study in Patients Suffering From Moderate to Severe Nasal Congestion
To demonstrate the safety and effectiveness of Sonu for the treatment of patients suffering from moderate to severe nasal congestion.
- Trial name
- SCORE (NCT05821842)
- Testing
- Sonu
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Third Wave Therapeutics
Chronic Obstructive Pulmonary Disease, COPD
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02449018
- Testing
- QBW251
- Where
- 16 sites in United States, Poland
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Asthma
Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.
- Trial name
- NCT00587288
- Testing
- Reslizumab, Saline
- Where
- 30 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Ception Therapeutics